CEO Stephen Mahoney was paid $6,776,249 in fiscal year 2025, ↑ up 506.4% from fiscal year 2024, the 50th percentile of its disclosed peer group (SEC filing 0001193125-26-160344 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,776,249 ↑ Stephen Mahoney total, FY2025 | 50th CEO pay percentile vs peers | 15.4:1 CEO-to-median pay ratio | 96.41% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
VRDN's next annual pay disclosure, estimated April 9, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Stephen Mahoney | $700,000 | $0 | $1,058,098 | $4,381,713 | $630,000 | $0 | $6,438 | $6,776,249 |
| President, Chief Executive Officer | ||||||||
| Radhika Tripuraneni | 430,636 | 50,000 | 0 | 3,341,410 | 253,529 | 0 | 4,891 | 4,080,466 |
| Chief Medical Officer | ||||||||
| Thomas Beetham | 545,001 | 0 | 542,335 | 2,245,871 | 408,750 | 0 | 19,225 | 3,761,182 |
| Chief Operating Officer | ||||||||
| Seth Harmon | 480,000 | 0 | 361,230 | 1,495,898 | 288,000 | 0 | 17,651 | 2,642,779 |
| Chief Financial Officer | ||||||||
| Jennifer Tousignant | 469,911 | 50,000 | 297,985 | 1,233,979 | 281,946 | 0 | 18,094 | 2,351,915 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Stephen Mahoney | $6,776,249 | $1,117,454 | $12,479,521 | ↑ +5,658,795 |
| Radhika Tripuraneni | 4,080,466 | — | — | — |
| Thomas Beetham | 3,761,182 | 809,500 | 4,761,401 | ↑ +2,951,682 |
| Seth Harmon | 2,642,779 | 770,659 | 6,548,526 | ↑ +1,872,120 |
| Jennifer Tousignant | 2,351,915 | 4,911,024 | — | ↓ −2,559,109 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Viridian Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper VRDN reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name VRDN as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Arlene M. Morris | Independent Director | $271,402 |
| Chris Cain | Independent Director | $710,589 |
| Jeff Ajer | Independent Director | $598,246 |
| Jennifer K. Moses | Independent Director | $268,902 |
| Sarah Gheuens | Independent Director | $248,902 |
| Tomas Kiselak | Chair of the Board | $293,902 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director | 2026-05-11 | A | 1,176,470 | $17 | $19,999,990 | Common | Form 4 ↗ |
| Tomas Kiselak | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chris Cain | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Ajer | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer K. Moses | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Gheuens | Director | 2026-07-01 | A | 32,341 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Radhika Tripuraneni | Chief Medical Officer | 2026-08-14 | A | 40,000 | 13 | 528,400 | Common | Form 4 ↗ |
| Radhika Tripuraneni | Chief Medical Officer | 2026-08-14 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Tousignant | Chief Legal Officer | 2026-08-19 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Tousignant | Chief Legal Officer | 2026-08-19 | D | 10,000 | 25 | 245,000 | Common | Form 4 ↗ |
| Jennifer Tousignant | Chief Legal Officer | 2026-08-19 | A | 10,000 | 14 | 144,100 | Common | Form 4 ↗ |
| Jennifer Tousignant | Chief Legal Officer | 2026-08-19 | D | 4,212 | 25 | 103,194 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jennifer Tousignant | RSU | 2025-03-03 | — | — | 20,679 | — | $297,984 |
| Seth Harmon | RSU | 2025-03-03 | — | — | 25,068 | — | 361,230 |
| Radhika Tripuraneni | OPTION | 2025-03-10 | — | — | — | — | 3,341,409 |
| Stephen Mahoney | OPTION | 2025-03-03 | — | — | 440,565 | — | 4,381,712 |
| Thomas Beetham | RSU | 2025-03-03 | — | — | 37,636 | — | 542,335 |
| Stephen Mahoney | RSU | 2025-03-03 | — | — | 73,428 | — | 1,058,097 |
| Jennifer Tousignant | OPTION | 2025-03-03 | — | — | 124,072 | — | 1,233,979 |
| Thomas Beetham | OPTION | 2025-03-03 | — | — | 225,814 | — | 2,245,871 |
| Seth Harmon | OPTION | 2025-03-03 | — | — | 150,407 | — | 1,495,898 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jennifer Tousignant | $297,984 | $0 | $1,233,979 | 0.0% |
| Seth Harmon | 361,230 | 0 | 1,495,898 | 0.0% |
| Radhika Tripuraneni | 0 | 0 | 3,341,409 | 0.0% |
| Stephen Mahoney | 1,058,097 | 0 | 4,381,712 | 0.0% |
| Thomas Beetham | 542,335 | 0 | 2,245,871 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jennifer Tousignant | Option | 100,809 | 14.41 | — |
| Jennifer Tousignant | Option | 157,084 | 19.68 | — |
| Stephen Mahoney | RSU | 73,428 | — | 2,285,079 |
| Thomas Beetham | Option | 217,434 | 13.02 | — |
| Thomas Beetham | RSU | 37,636 | — | 1,171,232 |
| Seth Harmon | RSU | 25,068 | — | 780,116 |
| Seth Harmon | Option | 61,980 | 24.5 | — |
| Jennifer Tousignant | RSU | 20,679 | — | 643,530 |
| Stephen Mahoney | Option | 577,225 | 13.02 | — |
| Stephen Mahoney | Option | 357,960 | 14.41 | — |
| Radhika Tripuraneni | Option | 310,700 | 15.58 | — |
| Seth Harmon | Option | 122,206 | 14.41 | — |
| Thomas Beetham | Option | 183,474 | 14.41 | — |
| Seth Harmon | Option | 129,375 | 13.76 | — |
Our executive compensation program is guided by our overarching philosophy of tying the compensation of our executive officers to key, measurable short-term goals and granting long-term equity awards that will provide value when our stock price increases.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 83,512,086 | 3,113,724 | 213,336 | 96.41% | Passed |
| 2025 | 2025-06-24 | 56,046,366 | 15,957,526 | 38,340 | 77.84% | Passed |
| 2024 | 2024-06-20 | 32,797,468 | 23,748,216 | 23,862 | 58% | Passed |
| 2023 | 2023-06-16 | 22,946,964 | 12,351,317 | 21,844 | 65.01% | Passed |
| 2022 | 2022-06-08 | 13,209,757 | 2,389,695 | 6,443 | 84.68% | Passed |
| 2021 | 2021-06-11 | 5,031,016 | 28,374 | 20,635 | 99.44% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-02 | 96.41%a |
| 2025 | 2025-06-24 | 77.84%b |
| 2024 | 2024-06-20 | 58%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on the matter and will have no effect on the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted as votes cast on the matter and will have no effect on the outcome of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 15.4 : 1 |
|---|---|
| CEO total compensation | $6,776,249 |
| Median employee compensation | $439,114 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Chris CainIndependent · Science · Nominating (Chair) · Newly elected | $57,500 | $0 | $653,089 | — | $0 | $710,589 |
| Jeff AjerIndependent · Audit · Compensation · Newly elected | 57,500 | 0 | 540,746 | — | 0 | 598,246 |
| Tomas KiselakIndependent · Board Chair · Science (Chair) · Nominating | 92,500 | 0 | 201,402 | — | 0 | 293,902 |
| Arlene M. MorrisIndependent · Compensation (Chair) · Audit · Nominating | 70,000 | 0 | 201,402 | — | 0 | 271,402 |
| Jennifer K. MosesIndependent · Audit (Chair) · Compensation | 67,500 | 0 | 201,402 | — | 0 | 268,902 |
| Sarah GheuensIndependent · Science | 47,500 | 0 | 201,402 | — | 0 | 248,902 |
| Stephen MahoneyEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $201,402 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $392,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $392,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Viridian Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Viridian Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Soleno Therapeutics | 2024 | Anish Bhatnagar | $640,000 | $46,883,000 | $3,231,230 | $403,200 | $51,160,430 |
| 2 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Rhythm Pharmaceuticals | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 4 | Crinetics | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 5 | Morphic Holdings | 2023 | Praveen Tipirneni | 613,502 | 3,742,960 | 4,121,756 | 412,966 | 8,907,684 |
| 6 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 7 | Tarsus Pharmaceuticals | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 8 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 9 | Prothena | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 10 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 11 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Crinetics | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| Immunovant | 110% | not disclosed | No | Compensia |
| Morphic Holdings | 120% | Stock Options 50 · RSU 50 | not disclosed | Aon |
| Pliant Therapeutics | not disclosed | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| Prothena | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Rhythm Pharmaceuticals | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Soleno Therapeutics | not disclosed | not disclosed | not disclosed | Aon plc |
| Tarsus Pharmaceuticals | 108% | Options 50 · RSU 50 | No | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Stephen Mahoney | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “2025 Summary Compensation Table”. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778 |
| 2 | Section 01, Radhika Tripuraneni | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “2025 Summary Compensation Table”. As printed: 4,080,466. Filing ↗machine: r13 · c35 · span 399749–399758 |
| 3 | Section 01, Thomas Beetham | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “2025 Summary Compensation Table”. As printed: 3,761,182. Filing ↗machine: r10 · c35 · span 392146–392155 |
| 4 | Section 01, Seth Harmon | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “2025 Summary Compensation Table”. As printed: 2,642,779. Filing ↗machine: r5 · c35 · span 379407–379416 |
| 5 | Section 01, Jennifer Tousignant | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “2025 Summary Compensation Table”. As printed: 2,351,915. Filing ↗machine: r8 · c35 · span 387012–387021 |
| 6 | Section 03, Jennifer Tousignant RSU | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r10 · c29 · span 428622–428629 |
| 7 | Section 03, Seth Harmon RSU | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r7 · c17 · span 421345–421351 |
| 8 | Section 03, Radhika Tripuraneni OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r16 · c29 · span 441575–441584 |
| 9 | Section 03, Stephen Mahoney OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r5 · c29 · span 417776–417785 |
| 10 | Section 03, Thomas Beetham RSU | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r13 · c17 · span 434299–434305 |
| 11 | Section 03, Stephen Mahoney RSU | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t102 · r4 · c29 · span 415669–415678 |
| 12 | Section 03, Jennifer Tousignant OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r4 · c7 · span 353569–353576 |
| 13 | Section 03, Thomas Beetham OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r5 · c7 · span 356172–356179 |
| 14 | Section 03, Seth Harmon OPTION | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r3 · c7 · span 350944–350951 |
| 15 | Section 07, pay ratio | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “CEO Pay Ratio”. As printed: 15.4 : 1. Filing ↗ |
| 16 | Section 08, Chris Cain | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 710,589. Filing ↗machine: t131 · r3 · c11 · span 626951–626958 |
| 17 | Section 08, Jeff Ajer | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 598,246. Filing ↗machine: t131 · r7 · c11 · span 631439–631446 |
| 18 | Section 08, Tomas Kiselak | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 293,902. Filing ↗machine: t131 · r4 · c11 · span 628087–628094 |
| 19 | Section 08, Arlene M. Morris | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 271,402. Filing ↗machine: t131 · r5 · c11 · span 629198–629205 |
| 20 | Section 08, Jennifer K. Moses | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 268,902. Filing ↗machine: t131 · r6 · c11 · span 630335–630342 |
| 21 | Section 08, Sarah Gheuens | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 248,902. Filing ↗machine: t131 · r2 · c11 · span 625837–625844 |
| 22 | Section 08, Stephen Mahoney | DEF 14A | 2026-04-17 | 0001193125-26-160344 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Fairmount Funds Management LLC 2026-05-11 | Form 4 | 2026-05-13 | 0001104659-26-060294 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Tomas Kiselak 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294547 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Chris Cain 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294561 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Jeff Ajer 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294560 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Jennifer K. Moses 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294556 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Arlene M. Morris 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Sarah Gheuens 2026-07-01 | Form 4 | 2026-07-02 | 0001193125-26-294552 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Radhika Tripuraneni 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355735 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Radhika Tripuraneni 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355735 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jennifer Tousignant 2026-08-19 | Form 4 | 2026-08-20 | 0001193125-26-359636 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Jennifer Tousignant 2026-08-19 | Form 4 | 2026-08-20 | 0001193125-26-359636 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Jennifer Tousignant 2026-08-19 | Form 4 | 2026-08-20 | 0001193125-26-359636 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Jennifer Tousignant 2026-08-19 | Form 4 | 2026-08-20 | 0001193125-26-359636 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0001193125-26-254560 | Item 5.07 · say-on-pay result. As reported: 96.41% (votes for as printed: 83,512,086). Filing ↗ |
| 37 | Section 06, 2025 vote | Form 8-K | 2025-06-24 | 0001193125-25-145741 | Item 5.07 · say-on-pay result. As reported: 77.84% (votes for as printed: 56,046,366). Filing ↗ |
| 38 | Section 06, 2024 vote | Form 8-K | 2024-06-20 | 0001193125-24-164461 | Item 5.07 · say-on-pay result. As reported: 58% (votes for as printed: 32,797,468). Filing ↗ |
| 39 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 40 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 41 | Section 09b board cost (computed) | Computed | — | — | Cash 392,500 + equity 0 + all other 0 = 392,500, summed across the director compensation table rows.machine: formula: Σ = 392,500 |
| 42 | Soleno Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-22 | 0001193125-25-089274 | CEO total compensation as printed in Soleno Therapeutics's own proxy. As printed: 51,160,430. Filing ↗machine: r2 · c27 · span 288252–288262 |
| 43 | Immunovant, Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 44 | Rhythm Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 45 | Crinetics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics's own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 46 | Morphic Holdings, Section 10b CEO total | DEF 14A | 2024-04-25 | 0001679363-24-000035 | CEO total compensation as printed in Morphic Holdings's own proxy. As printed: 8,907,684. Filing ↗machine: r3 · c48 · span 295049–295058 |
| 47 | Viridian Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160344 | CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778 |
| 48 | Tarsus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001819790-26-000028 | CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 49 | AnaptysBio, Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 50 | Prothena, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001559053-26-000012 | CEO total compensation as printed in Prothena's own proxy. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025 |
| 51 | Pliant Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 52 | Erasca, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 53 | Section 10a, Tarsus Pharmaceuticals reciprocity | DEF 14A | — | 0001819790-26-000028 | Tarsus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
| 54 | Section 10a, Rhythm Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
| 55 | Section 10a, Morphic Holdings reciprocity | DEF 14A | — | 0001679363-24-000035 | Morphic Holdings's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
| 56 | Section 10a, Crinetics reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
| 57 | Section 10a, Soleno Therapeutics reciprocity | DEF 14A | — | 0001193125-25-089274 | Soleno Therapeutics names Viridian Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 58 | Section 10a, Pliant Therapeutics reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics names Viridian Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 59 | Section 10a, Immunovant reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant names Viridian Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 60 | Section 10a, AnaptysBio reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
| 61 | Section 10a, Prothena reciprocity | DEF 14A | — | 0001559053-26-000012 | Prothena's most recent proxy was read; its disclosed peer group does not include Viridian Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.